RBC Capital raised the firm’s price target on Gilead (GILD) to $105 from $100 and keeps a Sector Perform rating on the shares after its Q3 results. Yeztugo fell slightly short of expectations, but Q4 guide should reassure launch should not dramatically disappoint, while FY26 should look better, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Hookipa Pharma completes sale of HBV, HIV assets to Gilead
- Gilead price target raised to $150 from $145 at JPMorgan
- Gilead Sciences: Strong Q3 2025 Performance and Growth Potential Justify Buy Rating
- Gilead price target raised to $145 from $140 at Wells Fargo
- Gilead Sciences Reports Strong Q3 2025 Results